TWiV 941: Clinical update with Dr. Daniel Griffin
- Author
- Vincent Racaniello
- Published
- Sat 01 Oct 2022
- Episode Link
- https://www.microbe.tv/twiv/twiv-941/
In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses, further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave, effectiveness of Molnupiravir in high risk patients, and primary care and a distinct symptom pattern for long COVID.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Research assistant position with Amy Rosenfeld (pdf)
- Support MicrobeTV with a Spike t-shirt at Vaccinated.US
- Increase in Acute Respiratory illnesses among children and adolescents (CDC)
- Estimates of Monkeypox incubation period, generation time, reproduction number (CDC)
- Rapid increase in suspected SARS-CoV-2 reinfections (CDC)
- Infection prevention and control recommendations for healthcare providers (CDC)
- SARS-CoV-2 attack rate in vaccinated and unvaccinated household contacts (CDC)
- Breakthrough Infection by variants elicited immune response comparable to vaccine (JID)
- Interval between prior SARS-CoV-2 infection and booster vaccination impacts (CELL)
- Humoral immunity evasion of BA.4 and BA.5 subvariants (The Lancet)
- Outpatient Remdesivir prevents severe disease in organ transplant recipients (Am J Transplant)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Effectiveness of Molnupiravir in high risk patients (CID)
- Update on Long COVID for primary care (BMJ)
- Distinct symptom pattern emerges for COVID-19 long-haul (Scientific Reports)
- Dr. Griffin’s treatment guide (pdf)
- Contribute to Floating Doctors fundraiser at PWB
- Letters read on TWiV 941
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]
